Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve
Roger G Clerc1, Andrea Stauffer, Franziska Weibel
1F Hoffmann-La Roche Ltd, Basel, Switzerland.
Objective:
The increased mortality observed with the cholesteryl ester transfer protein inhibitor torcetrapib is partly due to increased aldosterone production and blood pressure. The mechanisms underlying these effects were investigated.
Methods:
Cytochrome P450 subunit 11B2 (aldosterone synthase), extracellular signal-regulated kinase (p44/42) and voltage-gated Cachannel alpha subunit mRNA profiling, aldosterone production, cytosolic calcium and RNA interference were assessed in adrenocarcinoma human cells (H295R). Telemetry was conducted in spontaneously hypertensive rats.
Results:
Torcetrapib and angiotensin II (Ang II) but not dalcetrapib (a structurally different cholesteryl ester transfer protein inhibitor) elevated both cytochrome P450 subunit 11B2 mRNA and aldosterone production in H295R cells at 6 h. At days 1-5, torcetrapib produced a sustained increase of cytochrome P450 subunit 11B2 mRNA, unlike Ang II. Although torcetrapib and Ang II potentiated the effect of 25-OH cholesterol and raised pregnenolone levels, torcetrapib increased neither cytosolic Ca at 5 min nor extracellular signal-regulated kinase1/2 phosphorylation, suggesting initially divergent pathways. Unlike Ang II, torcetrapib steroidogenesis was not affected by Ang II type 1 receptor antagonism or voltage-gated T-type Ca channel antagonism, but was blocked by several L-type Cachannel antagonists. In unbiased genome-wide screening, Ang II and torcetrapib modulated an overlapping but distinct set of genes in H295R cells. Torcetrapib, but not Ang II, upregulated mRNA levels of the L-type Ca channel alpha 1C subunit. In spontaneously hypertensive rat, torcetrapib had a potent hypertensive effect mediated by the L-type Ca channel.
Conclusion:
The unique steroidogenic and hypertensive side effects of torcetrapib may be linked and involve voltage-gated L-type Ca channels. Structurally unrelated cholesteryl ester transfer protein inhibitors such as dalcetrapib do not share this effect.
Insights
Cholesteryl ester transfer protein inhibitor torcetrapib increases aldosterone and blood pressure through L-type calcium channels. Unlike other CETP inhibitors, torcetrapib uniquely affects aldosterone production and causes hypertension.
Area of Science:
- Endocrinology
- Cardiovascular Pharmacology
- Molecular Biology
Background:
- Cholesteryl ester transfer protein (CETP) inhibitors have shown increased mortality.
- Torcetrapib, a CETP inhibitor, is associated with increased aldosterone production and blood pressure.
- The mechanisms behind torcetrapib's side effects require investigation.
Purpose of the Study:
- To investigate the mechanisms underlying torcetrapib-induced aldosterone production and hypertension.
- To compare the effects of torcetrapib with angiotensin II and a structurally different CETP inhibitor, dalcetrapib.
Main Methods:
- Aldosterone synthase (CYP11B2) mRNA profiling in H295R cells.
- Aldosterone production, cytosolic calcium, and ERK phosphorylation assays.
- RNA interference and genome-wide gene expression screening.
- Telemetry in spontaneously hypertensive rats.
Main Results:
- Torcetrapib and angiotensin II increased CYP11B2 mRNA and aldosterone production in H295R cells.
- Torcetrapib induced a sustained increase in CYP11B2 mRNA, unlike angiotensin II.
- Torcetrapib's steroidogenic effects were blocked by L-type calcium channel antagonists, unlike angiotensin II.
- Torcetrapib upregulated L-type calcium channel alpha 1C subunit mRNA and caused hypertension in rats.
Conclusions:
- Torcetrapib's unique steroidogenic and hypertensive effects are linked to voltage-gated L-type calcium channels.
- These side effects are not shared by structurally unrelated CETP inhibitors like dalcetrapib.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Feedback Regulation of Calcium Concentration
Various transmembrane receptors, such as G protein-coupled receptors (GPCRs), elicit a response to extracellular signals by increasing cytosolic calcium. Activated GPCRs...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ligand-Gated Ion Channel Receptor: Gating Mechanism

